» Articles » PMID: 23486013

CancerDR: Cancer Drug Resistance Database

Overview
Journal Sci Rep
Specialty Science
Date 2013 Mar 15
PMID 23486013
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer therapies are limited by the development of drug resistance, and mutations in drug targets is one of the main reasons for developing acquired resistance. The adequate knowledge of these mutations in drug targets would help to design effective personalized therapies. Keeping this in mind, we have developed a database "CancerDR", which provides information of 148 anti-cancer drugs, and their pharmacological profiling across 952 cancer cell lines. CancerDR provides comprehensive information about each drug target that includes; (i) sequence of natural variants, (ii) mutations, (iii) tertiary structure, and (iv) alignment profile of mutants/variants. A number of web-based tools have been integrated in CancerDR. This database will be very useful for identification of genetic alterations in genes encoding drug targets, and in turn the residues responsible for drug resistance. CancerDR allows user to identify promiscuous drug molecules that can kill wide range of cancer cells. CancerDR is freely accessible at http://crdd.osdd.net/raghava/cancerdr/

Citing Articles

HNCDrugResDb: a platform for deciphering drug resistance in head and neck cancers.

Palollathil A, Nandakumar R, Ahmed M, Velikkakath A, Nisar M, Nisar M Sci Rep. 2024; 14(1):25327.

PMID: 39455682 PMC: 11511878. DOI: 10.1038/s41598-024-75861-9.


Cancer pharmacoinformatics: Databases and analytical tools.

Kamble P, Nagar P, Bhakhar K, Garg P, Sobhia M, Naidu S Funct Integr Genomics. 2024; 24(5):166.

PMID: 39294509 DOI: 10.1007/s10142-024-01445-5.


Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.

Zhang W, Zheng X, Coghi P, Chen J, Dong B, Fan X Front Immunol. 2024; 15:1438030.

PMID: 39206192 PMC: 11349682. DOI: 10.3389/fimmu.2024.1438030.


Bioinformatics tools and resources for cancer and application.

Huang J, Mao L, Lei Q, Guo A Chin Med J (Engl). 2024; 137(17):2052-2064.

PMID: 39075637 PMC: 11374212. DOI: 10.1097/CM9.0000000000003254.


DRMref: comprehensive reference map of drug resistance mechanisms in human cancer.

Liu X, Yi J, Li T, Wen J, Huang K, Liu J Nucleic Acids Res. 2023; 52(D1):D1253-D1264.

PMID: 37986230 PMC: 10767840. DOI: 10.1093/nar/gkad1087.


References
1.
Sadikovic B, Al-Romaih K, Squire J, Zielenska M . Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics. 2009; 9(6):394-408. PMC: 2691666. DOI: 10.2174/138920208785699580. View

2.
Tursz T, Andre F, Lazar V, Lacroix L, Soria J . Implications of personalized medicine--perspective from a cancer center. Nat Rev Clin Oncol. 2011; 8(3):177-83. DOI: 10.1038/nrclinonc.2010.222. View

3.
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

4.
Gronbaek K, Hother C, Jones P . Epigenetic changes in cancer. APMIS. 2007; 115(10):1039-59. DOI: 10.1111/j.1600-0463.2007.apm_636.xml.x. View

5.
Gifford R, Liu T, Rhee S, Kiuchi M, Hue S, Pillay D . The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics. 2009; 25(9):1197-8. PMC: 2672634. DOI: 10.1093/bioinformatics/btp134. View